Cephalon Inc.
41 Moores Road
Frazer,
PA 19355
United States - Map
Phone: 610-344-0200
Fax: 610-738-6590
Web Site: http://www.cephalon.com
| Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The companys pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa. The company was founded in 1987 and is headquartered in Frazer, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Frank Baldino Jr., 57
Founder, Chairman, Chief Exec. Officer and Pres |
$
3.02M |
$
4.77M | Mr. Kevin Buchi , 54
Chief Operating Officer |
$
880.00K |
$
0 | Mr. Carl A. Savini , 60
Chief Admin. Officer and Exec. VP |
$
773.00K |
$
0 | Dr. Peter E. Grebow Ph.D., 63
Exec. VP of Worldwide Technical Operations |
$
784.00K |
$
1.53M | Mr. Wilco Groenhuysen ,
Chief Financial Officer and Exec. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.51% Nasdaq 
Profile
